Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Pulmonx Corp (LUNG)
|
Add to portfolio |
|
|
|
| Price: |
$35.65
| | Metrics |
| OS: |
38.0
|
M
| |
-45
|
% ROE
|
| Market cap: |
$1.36
|
B
| |
-83
|
% ROIC
|
|
Net cash:
|
$110
|
M
| |
$2.90
|
per share
|
|
EV:
|
$1.25
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($59.8)
|
M
| |
|
|
|
EBIT
|
($61.4)
|
M
| |
|
|
| EPS |
($1.62)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-05-19 | Dec-31-18 | Dec-05-18 |
| Revenues | 53.7 | 48.4 | 32.7 | 32.6 | 32.6 | 20.0 | 20.0 |
| Revenue growth | 10.8% | 47.9% | 0.4% | 62.9% | 62.9% | | |
| Cost of goods sold | 13.8 | 12.8 | 11.5 | 10.2 | 10.2 | 7.7 | 7.7 |
| Gross profit | 39.9 | 35.6 | 21.2 | 22.4 | 22.4 | 12.3 | 12.3 |
| Gross margin | 74.3% | 73.6% | 64.8% | 68.8% | 68.8% | 61.4% | 61.4% |
| Selling, general and administrative | 83.1 | 69.9 | 46.1 | 34.2 | 34.2 | 20.3 | 20.3 |
| Research and development | 15.4 | 13.1 | 7.5 | 6.0 | 6.0 | 7.0 | 7.0 |
| EBITA | -58.5 | -47.2 | -32.2 | -17.7 | -17.8 | -15.0 | -15.1 |
| EBITA margin | -109.1% | -97.5% | -98.5% | -54.4% | -54.7% | -74.7% | -75.2% |
| Amortization of intangibles | 0.1 | 0.1 | 0.1 | 0.1 | | 0.1 | |
| EBIT | -58.6 | -47.3 | -32.3 | -17.8 | -17.8 | -15.1 | -15.1 |
| EBIT margin | -109.3% | -97.7% | -98.8% | -54.7% | -54.7% | -75.2% | -75.2% |
| Pre-tax income | -58.6 | -48.3 | -32.0 | -20.3 | -20.3 | -18.5 | -18.5 |
| Income taxes | 0.4 | 0.3 | 0.2 | 0.4 | 0.4 | 0.0 | 0.0 |
| Net income | -58.9 | -48.7 | -32.2 | -20.7 | -20.7 | -18.5 | -18.5 |
| Net margin | -109.8% | -100.5% | -98.5% | -63.5% | -63.5% | -92.4% | -92.4% |
| |
| Diluted EPS | ($1.59) | ($1.35) | ($3.16) | ($11.66) | ($11.66) | ($11.03) | ($11.03) |
| Shares outstanding (diluted) | 37.1 | 36.1 | 10.2 | 1.8 | 1.8 | 1.7 | 1.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|